Teva Pharmaceutical Industries (TEVA) Equity Average (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Equity Average across 18 years of filings, most recently posting $8.1 billion for Q1 2026.

• Quarterly Equity Average rose 38.57% year-over-year to $8.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 billion (up 38.57% YoY) and the FY2025 annual result came in at $6.6 billion, down 1.57% from the prior year.
• Equity Average climbed to $8.1 billion in Q1 2026, from $7.6 billion in the prior quarter.
• Over five years, Equity Average peaked at $10.8 billion in Q1 2022 and troughed at $5.8 billion in Q1 2025.
• A 5-year average of $7.9 billion and a median of $7.8 billion in 2023 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2025 — Equity Average declined 25.66% — and 2026, when it surged 38.57%.
• Tracing TEVA's Equity Average over 5 years: stood at $9.1 billion in 2022, then decreased by 14.31% to $7.8 billion in 2023, then slipped by 24.17% to $5.9 billion in 2024, then grew by 28.91% to $7.6 billion in 2025, then increased by 6.45% to $8.1 billion in 2026.
• Business Quant data shows TEVA's Equity Average at $8.1 billion in Q1 2026, $7.6 billion in Q4 2025, and $7.0 billion in Q3 2025.